Craft
  • Home
  •  / GBT (Global Blood Therapeutics)
GBT (Global Blood Therapeutics)

GBT (Global Blood Therapeutics)

Revenue

$194.7 M

FY, 2021

Market Capitalization

$4.4 B

2022-10-05

GBT (Global Blood Therapeutics) Summary

Company summary

Overview
GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. The Company develops its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in an ongoing Phase 2a study in patients with idiopathic pulmonary fibrosis.
Type
Public
Status
Active
Founded
2012
HQ
South San Francisco, CA, US | view all locations
Website
https://www.gbt.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Ted W Love

    Ted W Love, President and Chief Executive Officer

  • Jung E Choi

    Jung E Choi, Chief Business and Strategy Officer

    • Jeffrey Farrow

      Jeffrey Farrow, Chief Financial Officer

    • Nazila Habibizad

      Nazila Habibizad, Executive Vice President of Operations

    LocationsView all

    5 locations detected

    • South San Francisco, CA HQ

      United States

      181 Oyster Point Blvd

    • Paris, IDF

      France

      Gare Montparnasse, 46 bis Av. du Maine

    • Berlin, BE

      Germany

      Kollhoff-Tower, Potsdamer Platz 1

    • Baar, ZG

      Switzerland

      Neuhofstrasse 12

    • London, England

      United Kingdom

      Tallis House, 2 Tallis St, Blackfriars

    GBT (Global Blood Therapeutics) Financials

    Summary financials

    Footer menu